We are live on ! Find out more
MIST icon

Milestone Pharmaceuticals
MIST

25 hedge funds and large institutions have $350M invested in Milestone Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 25 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

53.41% more ownership

Funds ownership: 0% → 53.41% (+53%)

Holders
25
Holders Change
+25
Holders Change %
–
% of All Funds
0.54%
Holding in Top 10
4
Holding in Top 10 Change
+4
Holding in Top 10 Change %
% of All Funds
0.09%
New
25
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RI
RTW Investments
New York
+$72.6M
2
NHAS
Novo Holdings A/S
Denmark
+$55.1M
3
VMI
VHCP Management III
New York
+$42.6M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$26.8M
5
BC
Boxer Capital
California
+$22.7M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
RI
1
RTW Investments
New York
$91M +$72.6M +3,521,856 New
NHAS
2
Novo Holdings A/S
Denmark
$72.6M +$55.1M +2,674,470 New
VMI
3
VHCP Management III
New York
$56.1M +$42.6M +2,066,529 New
T. Rowe Price Associates
4
T. Rowe Price Associates
Maryland
$35.3M +$26.8M +1,299,946 New
BC
5
Boxer Capital
California
$29.9M +$22.7M +1,102,194 New
ACP
6
Acuta Capital Partners
California
$9.42M +$7.16M +347,000 New
Invesco
7
Invesco
Georgia
$8.82M +$6.7M +325,000 New
BBA
8
Baker Bros. Advisors
New York
$7.24M +$5.5M +266,667 New
FCM
9
Farallon Capital Management
California
$6.79M +$5.16M +250,000 New
Adage Capital Partners
10
Adage Capital Partners
Massachusetts
$6.52M +$4.95M +240,000 New
GTC
11
Ghost Tree Capital
New York
$6.52M +$4.95M +240,000 New
Fidelity Investments
12
Fidelity Investments
Massachusetts
$6.5M +$4.94M +239,600 New
ZP
13
Zimmer Partners
New York
$4.34M +$3.3M +160,000 New
VMI
14
VHCP Management II
New York
$4.03M +$3.06M +148,560 New
TCM
15
Tekla Capital Management
Massachusetts
$1.36M +$1.03M +50,000 New
DIM
16
DC Investments Management
Virginia
$1.06M +$805K +39,038 New
Millennium Management
17
Millennium Management
New York
$929K +$705K +34,199 New
OAM
18
Oxford Asset Management
United Kingdom
$834K +$634K +30,722 New
PCM
19
Pentwater Capital Management
Florida
$679K +$516K +25,000 New
LCM
20
Landscape Capital Management
New Jersey
$459K +$349K +16,924 New
TRCT
21
Tower Research Capital (TRC)
New York
$51K +$38.7K +1,877 New
Morgan Stanley
22
Morgan Stanley
New York
$19K +$14.4K +700 New
CCA
23
Catalyst Capital Advisors
New York
$14K +$10.3K +500 New
FDCDDQ
24
Federation des caisses Desjardins du Quebec
Quebec, Canada
$2.17K +$1.65K +80 New
WAP
25
Wealthcare Advisory Partners
Pennsylvania
$1K +$1.07K +52 New

MIST Hedge Fund Activity: Q2 2019 in Review

25 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Milestone Pharmaceuticals (MIST) for Q2 2019, worth a combined $350M.

Buyers outnumbered sellers: 25 funds opened new MIST positions and 0 closed out — a net gain of 25 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was RTW Investments, opening a new position worth an estimated $72.6M.

  • 25 institutional investors held Milestone Pharmaceuticals (MIST) as of Q2 2019, up from 0 in Q1 2019.
  • Funds reported $350M of Milestone Pharmaceuticals stock for Q2 2019.
  • 25 funds opened new Milestone Pharmaceuticals positions in Q2 2019 and 0 closed out, a net change of +25 holders.
  • The largest Milestone Pharmaceuticals buyer in Q2 2019 was RTW Investments, an estimated $72.6M added.

Based on aggregated 13F filings for Q2 2019.